[A comparative study on effect of bacterial load in diabetic foot ulcers dealing with iodophor and rivanol

Wenzhong Chen1, Kai Xu, Hui Zhang

  • 1Department of Plastic Surgery, No.2 Hospital, Shanxi Medical University, Taiyuan Shanxi, 030001, P.R. China.

Abstract

Insights

Both iodophors and rivanol reduce bacterial load in diabetic foot ulcers (DFUs). Iodophors demonstrated superior sterilizing and bacteriostatic effects compared to rivanol 24 hours post-treatment.

Area of Science:

  • Microbiology
  • Dermatology
  • Infectious Diseases

Background:

  • Diabetic foot ulcers (DFUs) are prone to bacterial infections, complicating wound healing.
  • Controlling bacterial load is crucial for managing DFUs and preventing further complications.

Purpose of the Study:

  • To compare the efficacy of iodophors and rivanol in reducing bacterial load on DFU surfaces.
  • To evaluate the antimicrobial effects of these agents over time.

Main Methods:

  • A randomized controlled trial involving 30 DFU patients, divided into control, iodophor, and rivanol groups.
  • Bacterial samples were collected pre-treatment, immediately post-treatment, and 24 hours post-treatment.
  • Bacterial load was quantified through colony counts after cultivation.

Main Results:

  • Bacterial load decreased in all groups, with no significant immediate post-treatment differences.
  • Iodophors showed significantly greater bacterial reduction compared to control and rivanol groups at 24 hours.
  • No significant difference in bacterial reduction was observed between control and rivanol groups at 24 hours.

Conclusions:

  • Both iodophors and rivanol effectively reduce superficial bacteria in DFUs.
  • Iodophors exhibit superior sterilizing and bacteriostatic properties over rivanol for DFU treatment.
  • Topical antiseptics can significantly reduce bacterial burden in diabetic foot wounds.

Related Concept Videos

Diabetic Foot Ulcer01:31

Diabetic Foot Ulcer

Definition A diabetic foot ulcer (DFU) is a chronic, non-healing wound that develops in individuals with diabetes. It typically occurs on pressure-bearing areas such as the heel, metatarsal heads, or hallux, and carries a high risk of infection and amputation.Pathophysiology • The development of DFUs can be explained by four interconnected mechanisms: neuropathy, ischemia, infection, and impaired wound healing. • Neuropathy is the most common factor. Sensory neuropathy reduces pain perception,...
Hand hygiene01:23

Hand hygiene

Asepsis is the practice of preventing or breaking the chain of infection. The nurse employs aseptic techniques to prevent the spread of microorganisms and reduce the risk of diseases. Hand hygiene is the cornerstone of aseptic techniques and is classified into medical and surgical asepsis. Medical asepsis includes hand hygiene and the use of gloves. Surgical asepsis, or the sterile technique, refers to practices that render and keep objects and areas free of microorganisms.
Hand washing...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...